{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.000001","statisticalComment":"stratified","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.170","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.364","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.248","statisticalComment":"stratified","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"125","upperLimit":"174","value":"165"},{"groupId":"OG001","lowerLimit":"28","upperLimit":"34","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"Time to progression (TTP) was defined as the time from date of randomization to disease progression (based on central radiological assessment using modified RECIST \\[Response Evaluation Criteria in Solid Tumors\\] v.1.1). Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until until date of database cutoff (26 Jan 2012); study duration approximately 1 year","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Days"}